The intravenous pegloticase market is projected to witness significant growth between 2025 and 2035, driven by the increasing prevalence of treatment-resistant gout (TRG), rising demand for biologic therapies, and expanding healthcare infrastructure. The market is expected to grow from USD 4,160 million in 2025 to USD 15,140 million by 2035, expanding at a compound annual growth rate (CAGR) of 13.8% over the forecast period.
The market growth is set to be catalysed by increasing awareness of uric acid-lowering treatment and the recent developments in PEGylateduricase based therapies. Demand for intravenous pegloticase and other treatments of choice for refractory gout is on the rise. Furthermore, a positive reimbursement scenario and collaborations by leading players, along with clinical trials pertaining to enhanced formulations would further propel the market.
North America is dominated in the gout therapies market owing to developed healthcare infrastructure, growing prevalence of gout and high rates of biologic therapies adoption. Asia-Pacific is anticipated to witness at-high growth rate owing to increasing healthcare expenditure, improving accessibility to modern-day gout therapies along with rising geriatric population.
Metric Overview
| Metric | Value |
|---|---|
| Market Size (2025E) | USD 4,160 million |
| Market Value (2035F) | USD 15,140 million |
| CAGR (2025 to 2035) | 13.8% |
The intravenous pegloticase market is anticipated to expand robustly as the demand for advanced biologics continues to rise, driving the adoption of available treatment methods, along with a favorable pipeline in gout therapies. With the rising need for targeted, effective therapies for refractory gout, the market is set to continue to gain momentum throughout the forecast period.
Explore FMI!
Book a free demo
The intravenous pegloticase market dominates in North America due to the growing number of patients suffering from chronic gout and more patients being treated with biologic therapies. United States is the leading market on account of the well-established healthcare infrastructure, strong reimbursement policies, and availability of advanced treatment options.
Ongoing demand is driven by the increasing incidence of refractory chronic gout, especially in the elderly and those with renal co-morbidities. Furthermore, increasing awareness with respect to treatment methods and availability of important pharmaceutical producers aids the development of the market.
The market is projected to grow due to supportive regulatory approvals by the FDA, along with continuous research and development efforts for improved formulations. Yet, high costs for intravenous pegloticase treatment and reduced patient adherence to therapy, because of infusion-related reactions, are limiting factors.
Europe constitutes a major market for intravenous pegloticase, represented by Germany, the UK, France, and Italy. The rising number of severe gout patients and the preference of physicians toward the use of biologics over traditional urate-lowering therapies are some of the factors contributing to the growth of the market.
Favorable reimbursement policies, strong healthcare systems and the availability of intravenous as a more affordable formulation of pegloticase are additional factors that make the region one with high potential for drug exposure. In addition, medical companies are investing in clinical trials and expanding their sales channels for better market penetration. Nonetheless, strict regulatory landscapes and price pressures from government healthcare agencies could limit rapid adoption.
Intravenous pegloticase is a rapidly growing market in Asia-Pacific rising incidence of gout, rising healthcare spending and development of medical infrastructure. Countries like China, Japan, South Korea, and India are experiencing increasing gout incidences owing to changes in dietary habits, an ageing population, and a rise in metabolic disorders including diabetes and obesity.
Increased government programs for better availability of biologic drugs and expansion of multilocal pharmaceutical companies in the region is supporting market growth. But barriers like awareness, lower diagnosis rates and affordability are impeding wide-scale adoption.
Challenges: High Treatment Costs and Limited Accessibility
The high cost of treatment has hindered the growth of the intravenous pegloticase market, restricting patient access in underserved areas and also in developing regions. Pegloticase is indicated for patients with chronic gout who are refractory to conventional therapy; however,they are often expensive due to complicated processes for production, and limited competition. Moreover, limitations in reimbursement and strict regulatory approvals are obstacles to widespread adoption.
Opportunities: Growing Adoption of Biologic Therapies for Chronic Gout
Growing cases of chronic gout and acceptance of biologic therapy will drive growth for intravenous pegloticase market. Novel biotechnology strategies and new clinical trials examining enhanced formulations and co-therapeutic approaches will ultimately lead to further improvements in therapeutic effectiveness, reduction of immunogenicity, and an increased cohort of patients potentially eligible for pegloticase therapy.
Between 2020 to 2024, the market was progress and there was increasing awareness of chronic gout and rising adoption of biologics in patients unresponsive to standard urate-lowering therapies have led to steady growth in the market. Challenges including the immunogenicity of pegloticase and high treatment costs continued to inhibit broader market penetration.
Forecasting the years 2025 to 2035, drug formulation will evolve based on innovations such as PEGylation to increase stability and reduce side’s effect. This is expected to drive more research to combination therapies along with immunomodulators which addresses immunogenicity issues and better treatment effectiveness for wider patient base.
Market Shifts: A Comparative Analysis (2020 to 2024 vs. 2025 to 2035)
| Market Shift | 2020 to 2024 Trends |
|---|---|
| Regulatory Landscape | Stringent approval processes for biologic drugs |
| Technological Advancements | PEGylation techniques for extended drug activity |
| Industry Adoption | Limited to refractory gout patients |
| Supply Chain and Sourcing | Dependence on high-cost biologic manufacturing |
| Market Competition | Dominance of a single FDA-approved pegloticase product |
| Market Growth Drivers | Increased diagnosis and treatment of chronic gout |
| Sustainability and Energy Efficiency | Focus on optimizing biologic production processes |
| Consumer Preferences | Demand for effective but costly biologic treatments |
| Market Shift | 2025 to 2035 Projections |
|---|---|
| Regulatory Landscape | Streamlined regulatory pathways for biosimilar and combination therapies |
| Technological Advancements | Next-gen biologics with enhanced efficacy and reduced immunogenicity |
| Industry Adoption | Expansion of patient eligibility through immunomodulatory approaches |
| Supply Chain and Sourcing | Cost-efficient production methods and increased biosimilar competition |
| Market Competition | Entry of alternative formulations and biosimilar |
| Market Growth Drivers | Expanded treatment options and growing biologic drug adoption |
| Sustainability and Energy Efficiency | Implementation of sustainable biopharmaceutical manufacturing |
| Consumer Preferences | Preference for cost-effective, longer-lasting, and patient-friendly formulations |
North America, specifically the United States, holds a significant share of the intravenous pegloticase market, fuelled by the increasing incidence of chronic gout resistant to traditional treatments. Some key factors attributing to market growth are the rising use of biologics, positively favorable reimbursement policies and strong health care infrastructure.
Furthermore, the growth of the market is driven by the presence of major pharmaceutical companies that are investing in the research and development of advanced biologics. Demand is also being driven by patient awareness campaigns and educational initiatives for physicians about treatment options for refractory gout. Combination therapies with immunomodulators are undergoing clinical trials.
| Country | CAGR (2025 to 2035) |
|---|---|
| United States | 13.5% |
Intravenous pegloticase is steadily becoming established in the management of uncontrolled gout in the United Kingdom, as there is an increasing elderly population and cases of uncontrolled gout. With an expanded rheumatology care through the essential National Health Service (NHS) pathway, biologics can be made more widely available.
Furthermore the growing awareness of refractory gout management intervention by healthcare professionals has facilitated early diagnosis and appropriate treatment.
These advancements have not only positioned pegloticase as an integral part of clinical protocols but also facilitated its accessibility through specialized treatment centers, thus bolstering market expansion. Innovation of biosimilar competition and changing pricing regulations, however, might modify the marketplace dynamic long term.
| Country | CAGR (2025 to 2035) |
|---|---|
| United Kingdom | 13.2% |
Germany, France and Italy are among the primary contributors to the demand for intravenous pegloticase in Europe, making the EU an important territory in this market. The high prevalence of chronic gout, coupled with an aging population, has driven demand for innovative treatment solutions. The uptake of intravenous pegloticase will benefit from favorable regulatory frameworks by the European Medicines Agency (EMA) and improved healthcare access across member states.
Additionally, pharmaceutical companies are building their biologic portfolios through the development of new formulations and optimizing delivery options. Growing partnerships among biotechnology companies and other healthcare organizations to develop novel gout therapies are driving the market.
| Region | CAGR (2025 to 2035) |
|---|---|
| European Union | 13.3% |
Japan intravenous pegloticase market is driven by growing older population vulnerable to chronic gout diseases. A highly structured healthcare model with high patient awareness facilitates the early adoption of advanced biologic therapies.
Government initiatives encouraging development of helping drugs and faster regulatory paths to market add to this penetration. However, the growth may face challenges from strict pricing controls and the preference for alternative treatment options. However, heightened research in novel formulations and prolonged drug efficacy is likely to facilitate long-term market growth.
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 13.4% |
The growing number of gout cases, as well as rising healthcare spending levels,contextualize the growing potential market for intravenous pegloticase in South Korea. The country’s rapid progress in biologic manufacturing, together with regulatory support for innovative therapeutics, has provided a significant boost to the market. Moreover, physicians more frequently add pegloticase to management regimens for patients who have not responded to standard treatments.
In this context, the increasing number of biopharmaceutical companies, industry collaborations and investments in local manufacturing capabilities are likely to augment the market dynamics. Thus, the rise of telemedicine/telehealth and the advances in digital healthcare are also enhancing patient access to specialized treatments.
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 13.6% |
Intravenouspegloticase therapy treated the increasing prevalence of treatment-refractory gout and drove the sales growth for the uric acid-lowering therapy market. Intravenous pegloticase has been found to be effective in treating chronic hyperuricemia, particularly in cases that are refractory to other therapies. The market is segmented by age group, with adult patients forming the largest patient group, and indication, where patients with chronic gout contribute to the majority of the demand.
| Age Group | Market Share (2025) |
|---|---|
| Adult | 73.5% |
By 2025, 73.5% of the intravenous pegloticase market share is owned by the adult patient population. Adult males over 40 years of age have the highest prevalence of gout, mainly caused by metabolic disorders, lifestyle habits, and comorbidities like hypertension and chronic kidney disease. The need for intravenous pegloticase has been increasing in this cohort as patients have become resistant to standard urate-lowering therapies.
| Indication | Market Share (2025) |
|---|---|
| Chronic | 67.8% |
Chronic gout indication segment is expected to account coverage of 67.8% of the market by 2025. Long-term management strategies are often necessary for chronic hyperuricemia, as many patients experience recurrent and painful gout attacks.
Pegloticase is specifically useful for patients who are resistant to traditional xanthine oxidase inhibitors: hence it's one of the most significant therapeutic options for chronic gout settings. People are becoming more aware of specialized treatments, especially advanced biologic treatments, so the chronic indication segment will retain its high share.
Given the increasing prevalence of treatment-resistant chronic gout (tophaceous gout) and the rising trend of biologics adoption, the intravenous pegloticase market is expanding. Pegloticase is an enzyme therapy that is commonly utilized for those patients who fail to respond to standard xanthine oxidase inhibitors. To fortify market position, manufacturers are concentrating on extending clinical indications, enhancing drug formulations & securing regulatory approvals.
Market Share Analysis by Key Players & Manufacturers
| Company/Organization Name | Estimated Market Share (%) |
|---|---|
| Horizon Therapeutics plc | 40-50% |
| Teijin Pharma Ltd. | 10-15% |
| Selecta Biosciences, Inc. | 8-12% |
| Krystal Biotech, Inc. | 6-10% |
| Other Companies (Combined) | 18-30% |
| Company/Organization Name | Key Offerings/Activities (Month & Year) |
|---|---|
| Horizon Therapeutics plc | Expanded Krystexxa ® production for chronic refractory gout treatment in March 2024, addressing increasing demand. |
| Teijin Pharma Ltd. | Announced clinical trial results for a novel intravenous pegloticase formulation in May 2024, aimed at improving efficacy. |
| Selecta Biosciences, Inc. | Introduced SEL-212, an investigational immune-tolerant pegloticase therapy, in June 2024, reducing anti-drug antibodies. |
| Krystal Biotech, Inc. | Acquired regulatory approval for a new pegloticase -based biologic targeting gout-related complications in July 2024, expanding treatment options. |
Key Market Insights
Horizon Therapeutics plc (40%-50%)
Horizon has a leading position in the market with Krystexxa®, which is the only FDA approved pegloticase therapy for uncontrolled gout. The emphasis on growing production capacity and patient support initiatives bolsters the firm’s leadership.
Teijin Pharma Ltd. (10-15%)
Teijin Pharma is continuing to invest in next generation pegloticase formulations, including extended-release and combination therapy investigation.
Selecta Biosciences, Inc. (8-12%)
Selecta is developing an immune-tolerant pegloticase (SEL-212) that has the potential to decrease immunogenicity and extend duration of therapy.
Krystal Biotech, Inc. (6-10%)
Krystal Biotech: Expanding into biologic late-stage treatments that addresses gout, using gene therapy expertise to augment pegloticase permeability.
Other Contenders (18-30% Combined)
New production and development plans and drug combination therapies are made as part of clinical trials for new companies in the intravenous pegloticase market, as existing companies like tefu are also seeking new investments in Pegloticase biosimilar. Some of the other contributors include:
The overall market size for the intravenous pegloticase market was USD 4,160 million in 2025.
The intravenous pegloticase market is expected to reach USD 15,140 million in 2035.
The demand for intravenous pegloticase is expected to rise due to the increasing prevalence of treatment-resistant gout (TRG), rising demand for biologic therapies, and expanding healthcare infrastructure.
The top five countries driving the development of the intravenouspegloticase market are the USA, Germany, China, Japan, and the UK.
Adult patients and chronic indications are expected to dominate the market due to the high reliance on healthcare professionals for administration and monitoring of intravenous pegloticase therapy.
Intravenous Pegloticase Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
